Navigation Links
EntreMed to Present at BIO CEO and Investor Conference
Date:2/5/2008

ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO CEO and Investor Conference, to be held at the Waldorf-Astoria Hotel, February 11-13, 2008. Mr. Burns' presentation is scheduled for Tuesday, February 12, 2008 at 2:45 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &

Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. EntreMed Appoints Senior Vice President of Research and Development
4. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
10. inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
11. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Irvine, CA (PRWEB) , ... April 29, 2016 ... ... research leader in personalized pain medicine, is excited to announce the launch of ... to supporting public health studies, volunteerism, and education to promote the use of ...
(Date:4/29/2016)... April 29, 2016 According ... Market Research "Separation Systems for Commercial Biotechnology Market ... and Forecast 2015 - 2023", the separation systems ... 10,665.5 Mn in 2014 and is projected to ... to 2023 to reach US$ 19,227.8 Mn in ...
(Date:4/29/2016)... ... 29, 2016 , ... Summit for Stem Cell has received a $250,000 grant ... stem cell therapy for the treatment of Parkinson’s disease. The Summit research project is ... Scripps Research Institute in San Diego, CA. , The aim of of ...
(Date:4/29/2016)... , April 29, 2016 Elekta ... latest update to its industry-leading treatment planning software, is ... Monaco version 5.11 provides significant ... attain calculation speeds up to four times faster than ... With the industry,s gold standard Monte Carlo ...
Breaking Biology Technology:
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
(Date:3/17/2016)... , March 17, 2016 ABI Research, ... forecasts the global biometrics market will reach more ... 118% increase from 2015. Consumer electronics, particularly smartphones, ... fingerprint sensors anticipated to reach two billion shipments ... Dimitrios Pavlakis , Research Analyst at ABI ...
Breaking Biology News(10 mins):